Dr. Gail Roboz Appears on Good Morning AmericaPosted: November 20, 2012 Filed under: Accolades, Leukemia News, Physician Presentations | Tags: Blood Disorders, Gail Roboz, Gail Roboz MD, MDS, Myelodysplastic Syndrome, New York Presbyterian, Weill Cornell Comments Off on Dr. Gail Roboz Appears on Good Morning America
Dr. Gail Roboz was interviewed Tuesday, November 20th about Myelodysplastic Syndrome. Watch the interview below.
Dr. Gail Roboz Interviewed on Good Morning AmericaPosted: October 12, 2012 Filed under: Accolades, Physician Presentations | Tags: Blood Disorders, Gail Roboz, Gail Roboz MD, MDS, Myelodysplastic Syndrome Comments Off on Dr. Gail Roboz Interviewed on Good Morning America
To see the interview, click here.
Dr. Gail Roboz Interviewed on Good Morning America about Myelodysplastic SyndromePosted: August 31, 2012 Filed under: Leukemia News, Physician Presentations | Tags: Blood Disorders, Gail Roboz, Gail Roboz MD, MDS, Myelodysplastic Syndrome, New York Presbyterian, Weill Cornell Medical College Comments Off on Dr. Gail Roboz Interviewed on Good Morning America about Myelodysplastic Syndrome
To view the video, click here.
Dr. Gail Roboz speaks to ABC World News about MDSPosted: August 31, 2012 Filed under: Leukemia News, Physician Presentations, Uncategorized | Tags: Blood Disorders, Gail Roboz, Gail Roboz MD, MDS, Myelodysplastic Syndrome, Weill Cornell Comments Off on Dr. Gail Roboz speaks to ABC World News about MDS
To see the interview, click here.
Weill Cornell Medical College Selected to Join New MDS Clinical Research ConsortiumPosted: June 19, 2012 Filed under: Clinical Trials, Laboratory Research, Leukemia News | Tags: Gail Roboz, Gail Roboz MD, MDS, Myelodysplastic Syndrome, Weill Cornell, Weill Cornell Medical College Comments Off on Weill Cornell Medical College Selected to Join New MDS Clinical Research Consortium
MDS researchers join forces to advance patient treatments and outcomesPosted: June 19, 2012 Filed under: Clinical Trials, Laboratory Research | Tags: Blood Disorders, Gail Roboz, Gail Roboz MD, MDS, Myelodysplastic Syndrome Comments Off on MDS researchers join forces to advance patient treatments and outcomes
NewYork-Presbyterian/Weill Cornell Medical Center is 1 of 6 institutions selected to participate in new MDS clinical research consortium
NEW YORK (June 18, 2012) — NewYork-Presbyterian/Weill Cornell Medical Center is one of six institutions selected to join the newly-founded MDS Clinical Research Consortium. The Consortium’s mission is to significantly advance treatments and patient outcomes for Myelodysplastic Syndromes (MDS) through innovative research and clinical trials.
The five-year, $16 million multi-institution initiative is the first privately funded MDS research consortium in the United States. It is sponsored by the Aplastic Anemia & MDS International Foundation of Rockville, Md., and supported by the Edward P. Evans Foundation. The Consortium’s funding to Weill Cornell Medical College will support MDS research at NewYork-Presbyterian/Weill Cornell Medical Center.
MDS is a cancer of bone marrow stem cells that inhibits the body’s ability to produce healthy blood cells. The disease can be treated and, in some cases, controlled, but currently, the only cure is stem cell transplantation. The new Consortium will help fill a major gap in the United States for MDS-related clinical research by joining dedicated academic medical centers with a high volume of MDS patients, an established database of current and former patients and a significant track record of participation in MDS clinical trials. The collaboration will facilitate evaluation of promising new compounds, epidemiological studies and translational research studies leading to new classifications, treatments and procedures for MDS.
“MDS is an under-recognized disease. Sometimes we don’t know why a patient has developed MDS, but we do know that those who have been exposed to cancer chemotherapy and radiation therapy are at increased risk,” says Dr. Gail J. Roboz, Weill Cornell Medical College’s principal investigator for the Consortium and director of the Leukemia Program at NewYork-Presbyterian/Weill Cornell Medical Center. “This Consortium offers a wonderful opportunity to develop new therapies and also to profile patients using the latest, state-of-the-art technologies so we can start to understand who gets MDS and why.”
Other Consortium partners include the Cleveland Clinic’s Taussig Cancer Institute, Dana-Farber Cancer Institute, MD Anderson Cancer Center, H. Lee Moffitt Cancer Center and Research Institute and the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.
“One of the greatest challenges in research of rare diseases like MDS is having enough patients to conduct meaningful clinical trials. No single center can do it alone. This uniquely collaborative effort overcomes that barrier,” said John Huber, Executive Director of the Aplastic Anemia & MDS International Foundation. “To have these six leading MDS research centers working together in this way is unprecedented,” Huber added. The Aplastic Anemia & MDS International Foundation will expand its programs for MDS patients, their families, and caregivers and local physicians who support and complement the aims and purposes of the Consortium.
“We are extremely pleased to work in partnership with AA&MDSIF and these six outstanding Consortium members. This collaborative endeavor reflects Mr. Evans’ desire to support the highest quality MDS research, which will lead to improved treatments for patients and, ultimately, to finding a cure,” said an Evans Foundation trustee.
View video of Weill Cornell’s principal investigator, Dr. Gail J. Roboz, discussing MDS and the importance of the new MDS Clinical Research Consortium: http://www.youtube.com/watch?v=gBSqofQ1vdY .
Weill Cornell Medical College
Weill Cornell Medical College, Cornell University’s medical school located in New York City, is committed to excellence in research, teaching, patient care and the advancement of the art and science of medicine, locally, nationally and globally. Physicians and scientists of Weill Cornell Medical College are engaged in cutting-edge research from bench to bedside, aimed at unlocking mysteries of the human body in health and sickness and toward developing new treatments and prevention strategies. In its commitment to global health and education, Weill Cornell has a strong presence in places such as Qatar, Tanzania, Haiti, Brazil, Austria and Turkey. Through the historic Weill Cornell Medical College in Qatar, the Medical College is the first in the U.S. to offer its M.D. degree overseas. Weill Cornell is the birthplace of many medical advances — including the development of the Pap test for cervical cancer, the synthesis of penicillin, the first successful embryo-biopsy pregnancy and birth in the U.S., the first clinical trial of gene therapy for Parkinson’s disease, and most recently, the world’s first successful use of deep brain stimulation to treat a minimally conscious brain-injured patient. Weill Cornell Medical College is affiliated with NewYork-Presbyterian Hospital, where its faculty provides comprehensive patient care at NewYork-Presbyterian Hospital/Weill Cornell Medical Center. The Medical College is also affiliated with the Methodist Hospital in Houston. For more information, visit weill.cornell.edu.
Leukemia Program Director, Gail Roboz, Interviewed on CNN’s “The Situation Room”Posted: June 12, 2012 Filed under: Leukemia News, Physician Presentations, Uncategorized | Tags: Blood Disorders, Gail Roboz, Gail Roboz MD, MDS, Weill Cornell Comments Off on Leukemia Program Director, Gail Roboz, Interviewed on CNN’s “The Situation Room”
Dr. Roboz describes the symptoms and treatment of Myelodysplastic Syndrome. Click the image to view her interview.
New Clinical Trial: Combination Chemotherapy and Dasatinib in Treating Patients With Newly Diagnosed Acute Myeloid LeukemiaPosted: March 26, 2012 Filed under: Clinical Trials, Leukemia News | Tags: Acute Myeloid Leukemia, AML, blood cancer treatment, chemotherapy, Core Binding Factor Abnormality, dasatinib, Gail Roboz MD, NewYork Presbyterian Hospital, Weill Cornell Medical College Leave a comment
The Weill Cornell Leukemia Program is now recruiting patients for a new study, “CALGB 10801: A Phase II Study of Induction (Daunorubicin/Cytarabine) and Consolidation (High-Dose Cytarabine) Chemotherapy Plus Dasatinib and Continuation Therapy with Dasatinib Alone in Newly Diagnosed Patients with Core Binding Factor Acute Myeloid Leukemia (AML).”
The physician leading the study at Weill Cornell is Gail Roboz, MD. For more information or to see if you are eligible for the study, please contact Tania Curcio, RN at (212) 746-2571 or email Tania at firstname.lastname@example.org.
This is a clinical trial for patients with acute myeloid leukemia (AML) that possesses an abnormal molecular feature (a gene mutation). The purpose of this study is to test the safety and effectiveness of adding the drug dasatinib to a treatment regimen in patients with AML and to determine how well the leukemia responds to the treatment. The study is being done because currently available treatment is not effective in curing patients with this type of leukemia.
There are three parts to the treatment in this study. The first part of the therapy will test the safety and effectiveness of adding dasatinib to the standard combination of chemotherapy drugs used to treat AML that include daunorubicin and cytarabine. The second part of the therapy will test the safety and effectiveness of combining dasatinib with another chemotherapy treatment, consolidation therapy with high-dose cytarabine. Finally, the third part of the therapy will test the effectiveness of the use of dasatinib alone for 12 months during continuation therapy.
Patients will receive therapy for about 18 months on study. After you are finished with the therapy, you will be asked to visit the office for follow-up at least every 2 months for 2 years, then every 3 months for 2 years, then yearly for a maximum of 10 years from when you entered the study.
- Men and women age 18 and older
- Acute myeloid leukemia (AML with Core Binding Factor (CBF) abnormality
- No prior chemotherapy for leukemia or myelodysplasia
- Detailed eligibility reviewed when you contact the study team
Dr. Roboz Speaks on Genomics in AMLPosted: January 18, 2012 Filed under: Laboratory Research, Leukemia News, Patient Education, Physician Presentations | Tags: Acute Myeloid Leukemia, AML, Blood Disorders, cancer treatment, Gail Roboz, Gail Roboz MD, Leukemia, Leukemia Treatment Comments Off on Dr. Roboz Speaks on Genomics in AML
Dr. Gail Roboz spoke with ecancertv at ASH 2011 in San Diego about the major genomic research on acute myeloid leukaemia. There has been a lot of recent success on identifying mutations and abnormalities in AML; however, Prof Roboz believes that the discovery period with genomic research is coming to an end and a move towards clinical trials and targeted therapies need to be developed. The largest development has been the role of stems cell in research and how to target the cells that are left over after chemotherapy.
Oral Chemotherapy Bill Signed Into Law in New York StatePosted: October 3, 2011 Filed under: Leukemia News | Tags: cancer treatment, Gail Roboz MD, health insurance, Leukemia Treatment, oral chemotherapy, Weill Cornell Medical College Comments Off on Oral Chemotherapy Bill Signed Into Law in New York State
On September 23 New York Governor Andrew Cuomo signed into law a bill that requires health plans to cover orally administered chemotherapy treatments at a cost equal to intravenously or injected chemotherapy treatments. The bill will go into effect January 2012.
Traditional intravenous chemotherapy drugs administered in a hospital or clinic are often included as a medical benefit under a patient’s health insurance plan. However, many oral chemotherapies are defined as a prescription benefit and frequently require much higher out-of-pocket costs for patients, or they have been unavailable to patients with financial caps on their prescription benefit.
“Many of our patients with leukemia and bone marrow disorders will directly benefit from this important new bill,” said Dr. Gail J. Roboz, Director of the Weill Cornell Leukemia Program. ” I am so proud that one of my patients was instrumental in this important accomplishment.”